The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A randomized phase II trial of MEK and CDK4/6 inhibitors vesus tipiracil/trifluridine (TAS-102) in metastatic KRAS/NRAS mutant (mut) colorectal cancer (CRC).
 
Michael Sangmin Lee
Consulting or Advisory Role - Pfizer
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Pfizer (Inst); Rafael Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Tyler J. Zemla
No Relationships to Disclose
 
Kristen Keon Ciombor
Consulting or Advisory Role - Array BioPharma; Bayer; Foundation Medicine; Merck; Natera; Pfizer; Research to Practice; Taiho Pharmaceutical
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Incyte (Inst); Incyte (Inst); MedImmune (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Nucana (Inst); Onyx (Inst); Pfizer (Inst); Pfizer/Calithera (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Array BioPharma
 
Autumn Jackson McRee
Honoraria - Cor2Ed
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Cor2Ed
 
Mehmet Akce
Consulting or Advisory Role - Eisai; Exelixis; GlaxoSmithKline; Ipsen; QED Therapeutics
Research Funding - Bristol-Myers Squibb-Ono Pharmaceutical (Inst); Eisai (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Polaris (Inst); RedHill Biopharma (Inst); Tesaro (Inst); Xencor (Inst)
 
Shaker R. Dakhil
No Relationships to Disclose
 
Brandy L. Jaszewski
No Relationships to Disclose
 
Fang-Shu Ou
Consulting or Advisory Role - SC Liver Research Consortium
 
Tanios S. Bekaii-Saab
Consulting or Advisory Role - Abbvie; Amgen (Inst); AstraZeneca; Bayer (Inst); BeiGene; Boehringer Ingelheim; Celularity; Daiichi Sankyo/UCB Japan; Eisai; Eisai; Exact Sciences; Foundation Medicine; Immuneering; Incyte (Inst); Ipsen (Inst); Janssen; Lilly (Inst); Natera; Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst); SOBI; Treos Bio
Patents, Royalties, Other Intellectual Property - Patent WO/2018/183488; Patent WO/2019/055687
Other Relationship - AstraZeneca; Exelixis; Lilly; Merck (Inst); Pancreatic Cancer Action Network
 
Scott Kopetz
Stock and Other Ownership Interests - Iylon; Lutris; MolecularMatch; Navire
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Genentech; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Servier; Xilis
Research Funding - Amgen (Inst); Array BioPharma (Inst); Biocartis (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Genentech/Roche (Inst); Guardant Health (Inst); Lilly (Inst); MedImmune (Inst); Novartis (Inst); Sanofi (Inst)